4 matches for your search in the start-up spotlight
rss
Further development of the SARS-CoV-2 antibody COR-101, which is currently in the clinical phase
13-Jul-2021
For the fast and efficient delivery of its innovative drug COR 101 against COVID-19, CORAT Therapeutics GmbH announces the partnership with Dermapharm Holding SE, a manufacturer of branded pharmaceuticals. The partnership is intended to accelerate clinical development and facilitate the expansion ...
COR-101 binds and inhibits all B.1.617 SARS-CoV-2 variants
24-Jun-2021
CORAT Therapeutics GmbH announced that its COR-101 antibody, currently in Phase Ib/II clinical trials against SARS-CoV-2, recognizes the latest aggressive “delta“ variant B.1.617.2. "COR-101 is under evaluation in hospitalized COVID-19 patients with moderate to severe symptoms. In this affected ...
COR-101 is a human antibody that blocks virus infection by binding to the spike protein
17-Mar-2021
CORAT Therapeutics GmbH obtained the regulatory approval as well as the favorable opinion from the central ethics committee to conduct the clinical phase Ib/II trial with its antibody COR-101 against COVID-19. COR-101 is a neutralizing human antibody that binds to the receptor binding domain ...
Antibody blocks the cell entry of SARS-CoV-2 and thus prevents the proliferation of corona viruses
20-Nov-2020
CORAT Therapeutics CEO Dr. Andreas Herrmann announced the completion of the production campaign of the first major batch of COR-101, which is now available for clinical trials. COR-101 is a fully human antibody developed in Braunschweig, Germany, which efficiently blocks the cell entry of ...
